Difference between revisions of "Piretanide"

Latest revision as of 15:46, 19 September 2010

This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2008)

Piretanide ([4-phenoxy-3-(1-pyrrolidinyl)-5-sulfamoyl-benzoic acid]INN) Piretanide has been synthesized in 1973 at Hoechst AG (Germany) as a diuretic and saluretic compound by using a new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups like sulfamoyl-, ester-,nitro-,amino-,hydroxy-,cyano-,halogen- or sulfonylimino-groups. Intensive studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics e.g.furosemide and bumetanide revealed its diuretic and saluretic potency with a more suitable dose/response (regression lines) and a more favourable Na/K excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive^[1] medication in Germany,France,Italy and other countries. Trade names: ARELIX,Eurelix,Tauliz. Bibliography : W.Merkel,D.Bormann,D.Mania,R.Muschaweck and M.Hropot,EUR.J.MED.Chem.-ChIM.THER.11,399 (1976) W.Merkel,D.Mania and D.Bormann,Liebigs Ann.Chem.461(1979)

References

1. ↑ [ Diuretics lecture, pharmacology and therapeutics by Dr. Chris John - Imperial College London]